UBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades Hot Comments

Exact Sciences (EXAS) PT Raised to $150 at OppenheimerOctober 28, 2020 8:33 AM Exact Sciences (EXAS) PT Raised to $150 at BairdOctober 28, 2020 6:34 AM Exact Sciences (EXAS) PT Raised to $155 at BTIGOctober 28, 2020 5:38 AM Citi Downgrades Exact Sciences (EXAS) to Neutral Following Surge on Thrive DealOctober 28, 2020 5:37 AM Exact Sciences (EXAS) Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45October 27, 2020 4:36 PM Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45October 27, 2020 4:35 PM Pre-Open Stock Movers 10/27 (SPI) (XLNX) (HOG) Higher; (CATB) (DXCM) (CHGG) Lower (more...)October 27, 2020 9:30 AM Form 8-K EXACT SCIENCES CORP For: Oct 27October 27, 2020 7:14 AM Form 424B2 EXACT SCIENCES CORP October 27, 2020 7:13 AM Exact Sciences (EXAS) to Sell $869 Million of Common Stock in Registered Direct OfferingOctober 27, 2020 7:12 AM Exact Sciences (EXAS) Q3 Revenues BeatOctober 27, 2020 7:10 AM Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct OfferingOctober 27, 2020 7:10 AM Form 10-Q EXACT SCIENCES CORP For: Sep 30October 27, 2020 7:06 AM Form 8-K EXACT SCIENCES CORP For: Oct 26October 27, 2020 7:04 AM Form 8-K EXACT SCIENCES CORP For: Oct 27October 27, 2020 7:04 AM Exact Sciences (EXAS) to Acquire Thrive Earlier Detection for Cash and Stock up to $2.15 BillionOctober 27, 2020 7:01 AM Exact Sciences Announces Third Quarter 2020 ResultsOctober 27, 2020 7:01 AM Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer ScreeningOctober 27, 2020 7:00 AM